Apyx Medical Corporation, formerly Bovie Medical Corporation, a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion in the cosmetic surgery market and as J-Plasma in the hospital surgical market, announced today that it has initiated subject enrollment in a US Investigational Device Exemption (IDE) clinical study evaluating the use of its Renuvion technology in dermal resurfacing procedures.

“The initiation of subject enrollment in this clinical study marks the continued advancement of our regulatory strategy to expand our addressable market opportunity in the US cosmetic surgery market by pursuing new clinical indications for target procedures,” said Charlie Goodwin, Chief Executive Officer, in a media release. “We expect the data from this study to support our submission for a new regulatory clearance that would enable us to market our Renuvion technology for dermal resurfacing procedures.”